Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Abstract | BACKGROUND: METHODS: In the current retrospective cohort study, we measured serum levels of the eight cytokines in 120 consecutive HCC patients who were treated with sorafenib. We evaluated the effects of increased expression of serum cytokines on progression-free survival (PFS) and overall survival (OS). RESULTS: Elevated expression of Ang-2 correlated both with significantly shorter PFS (hazard ratio (HR), 1.84; 95% confidence interval (CI), 1.21-2.81), and OS (HR, 1.95; 95% CI, 1.21-3.17). Patients with more than three cytokines expressed above the median similarly had significantly shorter PFS (HR, 1.98; 95% CI, 1.30-3.06) and OS (HR, 1.94; 95% CI, 1.19-3.22). Differences in OS were evident in cases with the evidence of macroscopic vascular invasion or extrahepatic metastasis. CONCLUSION: High expression of Ang-2 or more than cytokines in serum is associated with poor PFS and OS in HCC patients treated with sorafenib.
|
Authors | K Miyahara, K Nouso, Y Morimoto, Y Takeuchi, H Hagihara, K Kuwaki, H Onishi, F Ikeda, Y Miyake, S Nakamura, H Shiraha, A Takaki, M Honda, S Kaneko, T Sato, S Sato, S Obi, S Iwadou, Y Kobayashi, K Takaguchi, K Kariyama, Y Takuma, H Takabatake, K Yamamoto, Okayama Liver Cancer Group |
Journal | British journal of cancer
(Br J Cancer)
Vol. 109
Issue 8
Pg. 2072-8
(Oct 15 2013)
ISSN: 1532-1827 [Electronic] England |
PMID | 24045661
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiopoietin-2
- Antineoplastic Agents
- Cytokines
- Phenylurea Compounds
- Niacinamide
- Sorafenib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiopoietin-2
(blood)
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Hepatocellular
(blood, blood supply, drug therapy)
- Cohort Studies
- Cytokines
(blood)
- Female
- Humans
- Liver Neoplasms
(blood, blood supply, drug therapy)
- Male
- Middle Aged
- Neovascularization, Pathologic
(blood)
- Niacinamide
(analogs & derivatives, therapeutic use)
- Phenylurea Compounds
(therapeutic use)
- Retrospective Studies
- Sorafenib
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|